These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38830000)

  • 21. Opioid misuse epidemic: Addressing opioid prescribing and organization initiatives for holistic, safe and compassionate care.
    Naegle M; ; Mitchell AM; ; Flinter M; ; Dunphy L; ; Vanhook P; ; Delaney KR;
    Nurs Outlook; 2017; 65(4):477-479. PubMed ID: 28821312
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review.
    Simha S; Ahmed Y; Brummett CM; Waljee JF; Englesbe MJ; Bicket MC
    Reg Anesth Pain Med; 2023 Jan; 48(1):37-43. PubMed ID: 36202619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of COVID-19 on opioid treatment programs in the United States.
    Goldsamt LA; Rosenblum A; Appel P; Paris P; Nazia N
    Drug Alcohol Depend; 2021 Nov; 228():109049. PubMed ID: 34600258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
    Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
    BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 29. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of the adaptations in opioid agonist treatment during the COVID-19 pandemic: Focus on buprenorphine-based treatment.
    Ghosh A; Naskar C; Roub FE; Basu D
    J Opioid Manag; 2021; 17(7):119-131. PubMed ID: 34520033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
    Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
    J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic.
    Mannes ZL; Wheeler-Martin K; Terlizzi K; Hasin DS; Perry A; Pamplin JR; Crystal S; Cerdá M; Martins SS
    Prev Med; 2023 Dec; 177():107789. PubMed ID: 38016582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA; Zhang L; Kim HM; Frost MC
    Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increases in Naloxone Administrations by Emergency Medical Services Providers During the COVID-19 Pandemic: Retrospective Time Series Study.
    Khoury D; Preiss A; Geiger P; Anwar M; Conway KP
    JMIR Public Health Surveill; 2021 May; 7(5):e29298. PubMed ID: 33999828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
    Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
    J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.